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1078–5Recent evidence indicates that the risk of stroke symptoms in non-operated medically managed patients with asymptomatic
severe carotid stenosis has fallen significantly over the last 25 years. This suggests concurrent improvements in vascular
disease medical intervention efficacy. If the latest estimates of average annual stroke rate for non-operated patients are
reflective of contemporary medical intervention and surgical stroke/death rates match those of the randomised trials, the
current implication is that carotid surgery will not offer a stroke prevention advantage over medical intervention alone.
Furthermore, it is still not possible to identify patients with asymptomatic severe carotid stenosis with a higher than
average ipsilateral stroke risk despite current medical intervention. Even if such patients were one day reliably identified,
they could also be at higher risk of stroke/death from instrumental intervention (surgery, angioplasty or stenting) and
randomised trials will be required before being justification in routine clinical practice.
 2008 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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‘‘High risk plaque, high risk patient or high risk proce-
dure?’’ Naylor & Golledge, Eur J Vasc Endovasc
Surg 2006.
Appreciation of the best stroke prevention strategy
for patients with asymptomatic severe (50e99%) ath-
erosclerotic stenosis of the proximal internal carotid
artery (ICA) is important because this lesion (in wes-
ternised communities at least) becomes increasingly
prevalent in older age groups and causes an estimated
9e18% of all anterior circulation ischaemic strokes.1
The term ‘high risk’ has been used to describe patients
with asymptomatic severe carotid stenosis, sometimes
to justify the trial or use of interventions, like surgery
or stenting.2,3 However, ‘high risk’ is a non-specificsponding author. Dr. A. L. Abbott, MBBS, PhD, National
Research Institute, Austin Health, Level 1, Neurosciences
ng, Banksia Street, Heidelberg West, Victoria 3081, Australia.
address: a.abbott@nsri.org.au
884/000524 + 10 $34.00/0  2008 European Society for Vasculaand relative term. Therefore, to avoid confusion and
inappropriate action, the kind of risk and the compar-
ison being made must always be specified. For in-
stance, ‘high risk’ may refer to general patient or
specific plaque characteristics indicating a high risk
of serious complications, like stroke or death, such
that an intervention to reduce this risk should be con-
sidered. Conversely, ‘high-risk’ may refer to patient,
plaque or procedural characteristics indicating that
an intervention will sufficiently increase the risk of se-
rious complications such that the intervention should
be avoided.
This review consists of an appraisal of risk stratifi-
cation of patients with asymptomatic severe carotid
stenosis in the context of interventions aimed at re-
ducing risk. In this review, ‘asymptomatic’ means
the absence of previous symptoms of ipsilateral stroke
or TIA (except in the Asymptomatic Carotid Surgery
Trial [ACST] where about 11% of patients had suf-
fered an ipsilateral stroke/TIA >6 months before re-
cruitment4). Patients with previous stroke/TIA in
other vascular territories or with clinically silent brainr Surgery. Published by Elsevier Ltd. All rights reserved.
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tion. The most often studied risk in these patients is
that of stroke or death. The interventions examined
fall into three categories; (i) vascular disease medical
intervention, (ii) surgery to remove the stenosis (ca-
rotid endarterectomy [CEA]) and (iii) angioplasty
with/without stenting to compress the stenosis (endo-
vascular intervention).
Risk stratification with respect to asymptomatic
severe carotid stenosis more than 60% is important be-
cause patients with milder stenoses have about half the
annual ipsilateral stroke rate and are less likely to benefit
from instrumental intervention (CEA, angioplasty or
stenting).5 Furthermore, ipsilateral stroke symptoms
should be the main focus of attention because it is
more likely that ipsilateral (rather than contra-lateral)
stroke/TIA is caused by the carotid stenosis and will
be influenced by instrumental intervention. This reason-
ing is supported by the absence of data demonstrating
that instrumental intervention for asymptomatic
severe carotid stenosis reduces any territory (or total)
stroke rate independently of an effect on ipsilateral
stroke rate.
Vascular disease medical intervention is used to de-
scribe the combination of non-invasive strategies to
avoid or minimize vascular disease, including patient
education and the diagnosis and effective treatment
(non-pharmacological/pharmacological) of vascular
disease risk factors and symptoms. An aspect of med-
ical intervention is the identification of persons with
carotid vascular disease. Consequently, all studies of
asymptomatic severe carotid stenosis involve patients
undergoing at least some degree of vascular disease
medical intervention. This review will, therefore, ex-
amine the concept of the ‘high risk’ patient despite
medical intervention alone, and the patient at ‘high
risk’ because of additional instrumental intervention.The Patient at High-risk Despite Medical
Intervention Alone
Recent evidence indicates that the risk of ipsilateral
and any territory stroke/TIA in hospital identified,
non-operated patients with asymptomatic severe ca-
rotid stenosis has fallen significantly over the last 25
years, suggesting concurrent improvements in the
stroke prevention efficacy of vascular disease medical
intervention.1 This evidence was provided from a re-
view of all identified published prospective studies
of at least 100 patients with non-operated asymptom-
atic severe (50e75%) carotid stenosis with sufficient
published data for calculation of an average annual
rate of ipsilateral stroke and/or TIA. Nine studieswere identified5e13 and, more recently, comparable re-
sults have been reported from the Second Manifesta-
tions of ARTerial (SMART) disease study,14 see Table 1.
Many of the patients in these studies were identi-
fied because of cerebral or other symptoms of vascu-
lar disease, probably placing them at higher risk of
stroke than most community based patients with
asymptomatic severe carotid stenosis. With this in
mind, the most recent measures of average annual
rate of ipsilateral stroke ranged from 0.6e1.7%, and
the average annual rate of any territory (total) stroke
ranged from 0.8e2.2%.12e14 As can be seen from Table
1, these annual stroke rates are statistically no differ-
ent from those patients who received medical inter-
vention and surgery in the two larger and most
recent randomised CEA trials; the Asymptomatic Ca-
rotid Atherosclerosis Study (ACAS,10) and ACST.4 In
these two trials, the average annual rates of ipsilateral
and any territory stroke were 2.2%10 and 2.4%.4 As-
suming these more contemporary risk estimates for
non-operated patients accurately reflect outcomes in
current practice, the implication is that CEA (even at
the relatively high standard of the randomised trials)
probably no longer offers any significant stroke
prevention benefit over current medical intervention
alone.
Furthermore, in current clinical practice, surgery
could prove to be harmful if the perioperative stroke/
death rates exceed the 2e3% seen in the randomised
CEA trials4,10 and/or current vascular disease medical
intervention is even more effective than reported thus
far. Accordingly, it is probably more accurate to
consider comparable ‘routine practice’ patients with
asymptomatic severe carotid stenosis as high-risk
from CEA or angioplasty/stenting because accurate
measures of surgical outcome in routine practice are
not usually made. In addition, there are no randomised
trial data establishing a stroke prevention benefit from
endovascular intervention and the full impact of
current vascular disease medical intervention has not
been measured.1
CEA or stenting may be more effective in reducing
the risk of stroke/death in patients with asymptom-
atic severe carotid stenosis if patients at higher than
average risk (despite current medical intervention)
could be identified. Although the ‘high-risk’ patient
in this sense may exist, a reliable identification
method has been elusive. Proposed and/or investi-
gated risk stratification parameters are discussed be-
low. Risk stratification studies have usually been
performed in hospital identified patients and none
have received what would now be considered to be
‘optimal medical therapy’. This would require docu-
mentation of the prevalence and treatment of vascularEur J Vasc Endovasc Surg Vol 35, May 2008
Table 1. Average annual risk of the non-operated patient with asymptomatic severe (>50%) carotid stenosis#
n Follow-up (years)^ Ipsilateral stroke/TIA Ipsilateral stroke Any stroke/TIA Any stroke
Johnson et al., 19851 121 3.0D 19.0 (12.0, 26.0) 3.3 (0.1, 6.5) e e
Toronto Study, 19861 113 1.9 meanD (3.5 KMA) 7.8 (all TIA) (2.9, 12.7) e 14.8* (8.3, 21.3) e
Veterans’ Study, 19932 233 4.0 meanD 5.2 (2.3, 8.1) 2.4 (0.4, 4.4) 6.1 (3.0, 9.2) 3.0 (0.8, 5.2)
ACAS, 19952 834 2.7 medianD (5 KMA) 3.8* (2.5, 5.1) 2.2* (1.2, 3.2) e 3.5* (2.3, 4.7)
ECST, 19953 127 4.5D (3 KMA) e 1.9* (0, 4.3) e e
ACBS, 19971 357 3.1 mean (KMA not given) 4.2* (2.1, 6.3) 1.4* ( 0.2, 2.6) 5.8 (3.4, 8.2) 2.5* (0.9, 4.1)
NASCET, 20003 216 mean not given (5 KMA) e 2.0* (0.1, 3.9) e e
ACSRS Study, 20054,^^ 1115 3.3 mean (7 KMA) 3.4* (2.3, 4.5) 1.7* (0.9, 2.5) 4.1* (2.9, 5.3) 2.1* (1.3, 2.9)
ASED Study, 20054 202 2.9 mean (3 KMA) 3.1* (0.7, 5.5) 1.0* (0, 2.4) 5.1* (2.1, 8.1) 2.2* (0.2, 4.2)
SMART Study, 20071 221 4.1 mean^^^ e 0.6 (0, 1.6) e 0.7 (0, 1.8)
ACAS¼Asymptomatic Carotid Atherosclerosis Study, ECST¼ European Carotid Surgery Trial, ACBS¼Asymptomatic Cervical Bruit
Study, NASCET¼North American Symptomatic Carotid Endarterectomy Trial, ACST¼Asymptomatic Carotid Surgery Trial,
ACSRS¼Asymptomatic Carotid Stenosis and Risk of Stroke, ASED¼Asymptomatic Stenosis Embolus Detection, SMART¼ Second
Manifestations of ARTerial disease.
# Table adapted from Abbott et al., International Journal of Stroke, 2007.1
1 Subgroup from an observational cohort study.6,7,11,14
2 Medically managed subgroup from a randomised CEA trial for asymptomatic carotid stenosis.8,10
3 Medically managed subgroup from a randomised CEA trial for contralateral symptomatic carotid stenosis.9,5
4 A complete observational study cohort.13,12
^ Actual mean/median follow-up in bold print. Follow-up by KaplaneMeier analysis (KMA, in brackets) was used for rate calculation
when available.
* Rate derived from KaplaneMeier analysis.
D Parameter applies to the whole sample this subgroup with >50% stenosis was selected from.
^^ Rates courtesy of Prof A Nicolaides using ECST method of stenosis measurement (personal communication).
^^^ Mean followup for the subgroup with >50% asymptomatic carotid stenosis courtesy of Dr Goessens (personal communication).
526 A. L. Abbott and G. A. Donnandisease risk factors at baseline and during follow-up.
Further, on-going efforts to identify high-risk sub-
groups despite medical intervention alone are likely
to become more challenging (and possibly less cost ef-
fective) as the efficacy and implementation of medical
intervention continues to improve. Even if such high-
risk patients are one day reliably identified, these pa-
tients may then be at higher risk from instrumental in-
tervention and randomised trials of additional CEA or
angioplasty/stenting would be required before justifi-
cation in routine practice.i. Patient Features (Demographics and General
Vascular Disease Risk Factors)
So far studies of asymptomatic severe carotid stenosis
providing ipsilateral stroke and/or TIA rates (listed in
Table 1) have been too small for risk stratification by
age, sex or any other variable. In these studies the
mean patient age was 64e74 years and men generally
predominated, comprising 40e100% of patients. In
the Asymptomatic Carotid Stenosis and Risk of Stroke
(ACSRS) Study, the largest published and ongoing
study of asymptomatic severe carotid stenosis, neither
age nor sex has so far indicated a higher risk of ipsi-
lateral stroke with/without TIA.12,15
It may be anticipated, like stroke rates generally,16e18
that ipsilateral stroke rates in patients with asymptomatic
severe carotid stenosis increase with age. In addition, itEur J Vasc Endovasc Surg Vol 35, May 2008is likely that for a given age group the prevalence of se-
vere carotid atherosclerosis19,20 and ‘unstable’ appear-
ing asymptomatic carotid plaques21 as well as stroke
and other vascular disease complication rates will be
higher in men.16e18,22 Potential age-related gender dif-
ferences in carotid vascular disease, which may be less
noticeable in the extremes of old age, should be taken
into account in risk estimations. Ideally, risk stratifi-
cation in patients with asymptomatic severe carotid
stenosis should be performed by age for men and
women separately.
Other general vascular disease risk factors (like hy-
pertension or cardiac disease), in isolation, are poor
predictors of stroke and other vascular disease com-
plications because they are common among vascular
disease patients and a large proportion of vascular
events occur in their absence.23e25 In the ACSRS
Study, the combination of 90e99% asymptomatic ca-
rotid artery stenosis (using the European Carotid Sur-
gery Trial method of measurement26), a history of
contra-lateral TIAs and a creatinine exceeding
85 umol/L identified the highest risk subgroup, with
an average annual rate of ipsilateral stroke of 6.3%.12
However, this annual risk (yet to be independently
verified) is still relatively low compared to some re-
ported perioperative stroke/death rates for asymp-
tomatic patients (see below).
Although blood detected inflammatory or
biochemical markers, such as white blood cells, C-
reactive protein, lipoprotein-associated phospholipse
527‘High Risk’ Patient with Asymptomatic Carotid StenosisA2 activity and homocysteine levels may be useful in
general stroke or vascular disease risk stratifica-
tion,27e32 currently these are not effective in stratify-
ing ipsilateral stroke risk in patients with
asymptomatic severe carotid stenosis.ii. Carotid Plaque Features
Degree of stenosis
The predictive power of stenosis severity alone within
the 60e99% range has been inadequate for identifica-
tion of patients with sufficiently high risk to warrant
surgical intervention. The randomised surgical stud-
ies failed to show a correlation between stenosis se-
verity and CEA benefit.4,10 In the ASCRS Study,
combined ipsilateral cerebral ischaemic event rates
(stroke, TIA and amaurosis fugax) correlated with ste-
nosis severity,12 being highest (5.0%/year) for patients
with 90e99% stenosis. In these ‘high risk’ patients, the
average annual risk of ipsilateral stroke alone varied
from 1.0% to 6.3%, depending on serum creatinine
levels and any previous stroke symptoms.
Other carotid plaque features proposed as markers
of ipsilateral or general stroke/TIA risk include an oc-
cluded contralateral carotid artery.33 However, as dis-
cussed below, these patients may be at lower
spontaneous stroke risk. Other proposed high risk
markers include carotid wall motion34 or stenosis pro-
gression before symptoms occur.11,35 However, large
prospective studies testing these parameters are lack-
ing, and the influence of modern medical intervention
must be considered in any future studies.Plaque morphology
Plaque morphology may be divided into surface con-
tour and cross-sectional characteristics (or structure).
Most studies of carotid plaque morphology have em-
ployed ultrasound or conventional angiography, par-
ticularly among patients with any degree (>0%) of
carotid stenosis. An irregular surface and/or echolu-
cent texture (diffusely dark on ultrasound) or hetero-
geneous texture (mixed light and dark on ultrasound)
are features more strongly associated with past or
subsequent any territory stroke/TIA or other vascular
complications compared to a smooth surface and/or
homogeneous texture (diffusely bright on ultra-
sound).35e42 However, plaque imaging has not been
demonstrated to reliably stratify ipsilateral stroke risk
among patients with asymptomatic severe (>50e
75%) carotid stenosis.Johnson et al.6 in 1985, (Table 1), reported that pa-
tients with duplex determined >75% echolucent
(‘soft’) plaque had respective average annual rates of
ipsilateral stroke and ipsilateral stroke/TIA of about
6.3% and 31.0% (approximately 1.5e2.5 times higher
than for patients with >75% echogenic ‘dense’ or
bright plaques). Such high ipsilateral stroke/TIA rates
stratified by plaque morphology have not been re-
ported since, possibly influenced by a lowering of
stroke symptom risk in medically treated patients
with asymptomatic carotid stenosis since the early
1980s. By comparison, Nicolaides et al. reported that
70e99% asymptomatic (mainly echolucent or partly
echogenic) plaques carry an average ipsilateral stroke
rate of only about 2%/year, compared with about
0.14%/year for uniformly echogenic or calcified
plaques.43
Plaque imaging modalities are improving in tissue
characterization.28,44e46 However, the pathology itself
may ultimately limit clinically useful risk stratification
in patients with severe carotid stenosis. This is due to
heterogeneity of tissue types within the one pla-
que.47,48 In addition, although pathological features
associated with plaque instability (ulceration, plaque
haemorrhage/rupture and lumen thrombus) have
been seen in about 20e50% of symptomatic patients,
these have also been seen in about 15e45% of asymp-
tomatic carotid plaques.49e51 Further, in studies of pa-
tients with mixed symptomatic status, such
pathological features become increasingly common
as degree of stenosis increases from zero,39,49,52,53 con-
sistent with the finding that imaging-determined ir-
regular and heterogeneous plaques predominant in
high-grade carotid stenosis,42,53,54 including specifi-
cally asymptomatic cases.36,55iii. Intracranial Features
Preliminary transcranial Doppler studies of patients
with asymptomatic severe carotid stenosis indicate
that the detection of at least one or two microemboli
in the ipsilateral middle cerebral artery, although
a very sensitive marker of future ipsilateral stroke
and/or TIA risk, lacks specificity as most patients re-
main stroke/TIA free over an approximate 3-year fol-
lowup period.13 It is more likely that higher rates of
microembolism may be useful in risk stratification,
as is the case for microembolism associated with ca-
rotid endarterectomy.56 Of note, consistently micro-
embolic signal negative asymptomatic stenotic
carotid arteries are associated with a low risk of sub-
sequent stroke or TIA.13,57 Although results from
a larger and ongoing study are awaited withEur J Vasc Endovasc Surg Vol 35, May 2008
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these patients means that reliable automated emboli
detection techniques are required.13
Other proposed intracranial markers of ipsilateral
or any territory stroke/TIA risk include impaired ce-
rebrovascular reactivity,59 relative cerebral hypoperfu-
sion,60 magnetic resonance imaging detected
metabolic changes61 or the presence of asymptomatic
cerebral infarction.62 However, large prospective stud-
ies testing these parameters are lacking, and the influ-
ence of modern medical intervention must be
considered in any future studies.The Patient at High-Risk Because of
Instrumental Intervention
In the major randomised CEA trials of asymptomatic
carotid stenosis, the overall average perioperative risk
of stroke or death was 2.9%.4,8,10,63 These trial results
have been used to set a bench mark between benefi-
cial and harmful surgical intervention. Previous rec-
ommendations for surgery were usually conditional
upon an operative stroke/death risk less than 3%.64e67
As mentioned above, in current routine clinical prac-
tice, however, all medically treated patients with
asymptomatic severe carotid stenosis may be consid-
ered at relatively high risk of stroke or death caused
by CEA, even if the randomised trial surgical stan-
dards are matched. This is because of evidence that
the overall stroke prevention efficacy of medical inter-
vention has improved over the last 25 years and is
now at least as good as the combination of CEA and
medical intervention employed in the randomised
CEA trials conducted in 1983e2003.4,8,10
Assuming recent risk estimates for non-operated
patients accurately reflect outcomes in current prac-
tice, indications are that CEA would have to carry
an average stroke/death risk of perhaps <1% if it is
to offer a meaningful benefit over current vascular
disease medical intervention alone. However, there
is little evidence that general surgical standards
have improved (or even match) those seen in the
CEA randomised trials. In fact, concern has been
raised over higher perioperative stroke/death rates
reported in other settings. Perioperative mortality
rates of up to 14 or 25 times higher than in ACAS
have been reported among non-trial patients when
CEA is performed within trial and non-trial hospi-
tals.68 Higher peri-operative stroke/death rates for
asymptomatic patients have also been reported from
other randomised trials2, 69 and retrospective surveys
of surgical practice.70e72Eur J Vasc Endovasc Surg Vol 35, May 2008The SAPPHIRE (Stenting and Angioplasty with
Protection in Patients at High Risk for Endarterec-
tomy) Study, in which 71% of 334 patients recruited
were asymptomatic, has provided the first published
randomised results of stenting versus CEA for asymp-
tomatic severe carotid stenosis.2 The respective 30-day
procedural stroke/death rates were 5.4% and 4.6% for
asymptomatic patients who underwent CEA or stent-
ing. The relatively high procedural stroke/death rates
in SAPPHIRE, and in prospective stenting registries
for asymptomatic (5.8% in ARCHeR73) or mostly
asymptomatic patients (5.2% in CREATE74), have
been attributed to patient factors (such as degree of
stenosis and co-morbidities). However, the absence
of a comparison arm of medical intervention alone
for such ‘high risk’ asymptomatic patients makes it
impossible to judge the extent to which patient or pro-
cedural factors are responsible.
Several other randomised studies of endovascular
intervention versus CEA for asymptomatic carotid
stenosis are underway or being planned, most (unfor-
tunately) without comparison with current optimal
(or any) medical intervention alone (CREST,75 Ca-
RESS,76 ACST-2 [website: http:www.acst.org.uk] and
TACIT77). Of note, in several randomised trials of
CEA versus endovascular intervention for symptomatic
patients with severe carotid stenosis, the 30-day pro-
cedural stroke/death rate for one or both procedures
exceeded 6 or 7%,2,78e81 the threshold between benefi-
cial and harmful surgical intervention in this set-
ting.26,82e84 These observations emphasise the
importance of accurate assessment of procedural out-
comes from each centre offering routine procedures.
Further, inter-centre differences in major procedural
complication rates may not be immediately apparent
from meta-analyses showing overall similar results.85
Evidence with regard to the low overall risk of
stroke in patients with asymptomatic severe carotid
stenosis receiving current medical intervention alone
(and thus the relatively high overall risk of stroke or
death imposed by CEA) is recent and requires
a well designed and conducted clinical study for con-
firmation. In addition, (as now discussed) certain pa-
tient, plaque and procedural features have already
been recognised as indicators that CEA is likely to in-
crease the risk of stroke or death over medical inter-
vention alone.i. Patient and Plaque Features
It is clear that the risk of peri-operative stroke or death
is lower for asymptomatic compared to symptomatic
patients.86 Therefore, outcomes for these patients
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randomised CEA trials of asymptomatic severe ca-
rotid stenosis the main exclusion criteria were aspirin
intolerance, use of long term anticoagulants, post-
CEA carotid stenosis and conditions likely to compli-
cate surgery, prevent continuing participation or
cause disability or death within five years.4,10,75 About
25 and four patients, respectively, were screened for
every one randomised in ACAS and the Veterans Af-
fairs Cooperative Study.10,68,87 Although these pa-
tients were excluded because of the perception of
high risk imposed by CEA, the outcome of such pa-
tients with current (or any) vascular disease medical
intervention alone is unknown.
Of patients with asymptomatic moderate-severe
carotid stenosis included in randomised trials of
CEA or angioplasty/stenting or retrospective surveys
of clinical practice,88 there is evidence that
women,10,88 those with contra-lateral carotid occlu-
sion,5,89 the elderly75,88 and those with a history of
congestive heart failure88 are more likely to suffer
peri-procedural stroke or death or receive no long
term benefit from carotid surgery. In ACAS, patients
with a history of diabetes mellitus, contralateral si-
phon stenosis or no alcohol consumption had a higher
risk of perioperative stroke, while those with a history
of previous stroke, contralateral stenosis greater than
60% and no alcohol consumption had a higher perio-
perative risk of stroke, TIA, nonfatal MI or death.65
From studies of patients with mixed symptomatic
status, indicators of higher surgical stroke/death risk
are age beyond 75 years,90e92 female sex,90,92e94 contra-
lateral ICA stenosis or occlusion69,90 and stenosis of the
ipsilateral external carotid artery or carotid siphon,90
left sided procedure,69,95 carotid re-operation,96 sys-
tolic hypertension90 and previous angina or congestive
heart failure.97 From a registry of 418 mostly asymp-
tomatic patients, it has been reported that carotid
plaque echolucency increases the risk of stroke associ-
ated with carotid stenting.98ii. Procedural Factors
Surgical experience
The experience and expertise of the surgical team is
very important in determining procedural complica-
tion rates and was probably a key reason for the rela-
tively low stroke/death rates seen in the major
randomised CEA trials. Potential participating sur-
geons for the major randomised surgical trials were
selected based on personal records of acceptable an-
nual numbers of CEAs performed99 and/orprocedural stroke/death rates.4,87,99 In addition,
ACAS and ACST trial surgeons participated on the
understanding that they would be excluded from fur-
ther participation if complication rates were unaccept-
able.4,99,100 About 32% of applicant surgeons were
excluded from ACAS and operative stroke/death
rates were 2e3 times higher among them.99
Higher reported perioperative stroke/death rates
than those in the randomised CEA trials are more
likely when relatively few procedures (fewer than
about 10e50/centre or surgeon) are performed annu-
ally.68,95,101e106 Other complications of CEA (such as
wound haematoma, infection or dehiscence and
pneumonia) are also more likely when relatively few
procedures are performed annually.103
Other procedural factors
The lack of peri-operative antiplatelet therapy97,107,108
and use of angiography8,10 increase the risk of perio-
perative stroke, death and myocardial infarction
among asymptomatic or mixed asymptomatic/symp-
tomatic patients undergoing carotid endarterectomy.
Further, reported neurological complication and/or
mortality rates following CEA and angioplasty/stent-
ing are higher when neurologists are involved in pre
and post-intervention assessments.70,109,110Conclusion and Future Directions
The term ‘high risk’ in relation to patients with
asymptomatic severe carotid stenosis is a non-specific
and relative term and must always be specified if con-
fusion and inappropriate action are to be avoided. In
practice, this term usually refers to the patient at high
risk of stroke or death despite medical intervention
alone or at high risk of stroke or death because of ad-
ditional instrumental intervention. In both situations,
risk is dependent on patient risk factor profile and the
nature of the intervention(s) employed. To date hospi-
tal identified patients with asymptomatic severe ca-
rotid disease have been the focus of investigation.
For these patients there is evidence that the risk of
stroke/TIA has fallen significantly over the last 25
years, probably due to improvements in efficacy of
vascular disease medical intervention. Indications
are that it is inappropriate to use the relatively high
stroke rates from the earliest studies of non-operated
patients with asymptomatic severe, carotid stenosis
to justify instrumental intervention (CEA or stenting)
today.2 Overestimates of average annual stroke rates
for non-operated patients may also occur if derived
only from the first 12 months of followup (whenEur J Vasc Endovasc Surg Vol 35, May 2008
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and ipsilateral stroke rates are not differentiated.
If the most recent estimates of stroke risk in non-
operated patients with asymptomatic severe carotid
stenosis accurately reflect outcomes in current routine
practice, the implication is that CEA (even to the rela-
tively high standard seen in the randomised trials)
will not offer a stroke prevention advantage over cur-
rent medical intervention alone. In fact, CEA may be
dangerous given the general unavailability of accurate
measures of outcomes from routine surgical practice
and because the full potential of currently available
vascular disease medical intervention has not been as-
sessed. Even the most recent studies of patients with
asymptomatic severe carotid stenosis were not fully
interventional in the diagnosis and treatment of vas-
cular disease risk factors and/or have provided only
baseline descriptions of patient risk factors and med-
ical interventions employed.12e14
Carotid atherosclerosis, being a well recognised
marker of systemic vascular disease and relatively
easy to detect non-invasively, is an opportunistic win-
dow into general vascular health. Most important for
patients with carotid atherosclerosis (including those
with severe stenosis) is to assess the combined impact
of effective vascular disease medical interventions on
‘global vascular risk’,111 which is the risk of stroke,
myocardial infarction and other symptoms or death
due to vascular disease. Patients should be stratified
by markers of ‘global’ vascular risk, such as age, sex
and the presence or absence vascular disease symp-
toms. Study of hospital and community based patients
would allow assessment of early primary through
to late secondary prevention of vascular disease
complications. Although some may suggest repeated
randomised surgical studies for this purpose,112 well
conducted observational studies of contemporary
vascular disease medical intervention alone may be
preferable given the already recognised difficulties of
ensuring a surgical benefit in routine practice and the
cost-ineffectiveness of CEA in asymptomatic patients.1
Until now the kind of medical intervention which
specifically reduces stroke risk in patients with
asymptomatic carotid stenosis has been unknown.
Previously, medical intervention for many of these pa-
tients was directed by general vascular risk factors or
non-ipsilateral carotid vascular disease symptoms
rather than the presence of carotid stenosis itself.
Over the last 25 years our understanding of vascular
risk factors has evolved and effective therapies (in-
cluding the use of aspirin, statin agents and newer
anti-hypertensive agents) have become ‘common
place’. The apparent 25-year fall in risk of stroke
symptoms in non-operated asymptomatic patientsEur J Vasc Endovasc Surg Vol 35, May 2008with severe carotid disease is an indication that now
commonly employed vascular disease medical inter-
vention is effective in reducing the risk of stroke
caused by and otherwise associated with this lesion.
It is now time to educate the public about the benefits
expected from vascular disease medical intervention
in reducing everyone’s risk.25,113 After all, vascular
disease avoidance or minimisation depends chiefly
on an informed public to adopt a healthy lifestyle
and comply with appropriate use of medication.114
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